Psychiatric disorders associated with FXTAS

Current Psychiatry Reviews

Volumn 9, Issue 1, 2013, Pages 59-64

  Seritan, Andreea L ^a,b   Ortigas, Melina ^b   Seritan, Stefan ^c   Bourgeois, James A ^d   Hagerman, Randi J ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d MCMASTER UNIVERSITY   (Canada)

Author keywords

Anxiety; Depression; FMR1 premutation; FXTAS; Psychiatric disorders; Substance abuse

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; ATOMOXETINE; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE; GABAPENTIN; LAMOTRIGINE; LITHIUM; MEMANTINE; MIRTAZAPINE; OXCARBAZEPINE; PREGABALIN; QUETIAPINE; RISPERIDONE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TRAZODONE; VALPROIC ACID; ZIPRASIDONE;

ALCOHOLISM; ANXIETY DISORDER; ARTICLE; ATTENTION DEFICIT DISORDER; AUTISM; AUTOIMMUNE DISEASE; BIPOLAR DISORDER; COGNITIVE DEFECT; COGNITIVE THERAPY; DEGENERATIVE DISEASE; DEPRESSION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG MEGADOSE; EATING DISORDER; EXTRAPYRAMIDAL SYMPTOM; FIBROMYALGIA; FRAGILE X ASSOCIATED TREMOR ATAXIA SYNDROME; GAIT DISORDER; HEART DISEASE; HUMAN; HYPERTENSION; IMPULSE CONTROL DISORDER; INSOMNIA; KIDNEY DISEASE; LOW DRUG DOSE; MEMORY DISORDER; METABOLIC DISORDER; MIGRAINE; MOOD DISORDER; MYALGIA; NEUROPATHIC PAIN; NEUROPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSESSIVE COMPULSIVE DISORDER; ORTHOSTATIC HYPOTENSION; PANIC; PARANOIA; PARESTHESIA; PERIPHERAL NEUROPATHY; PHENOTYPE; PRIORITY JOURNAL; PROBLEM SOLVING; PSYCHOSIS; SEIZURE; SEX DIFFERENCE; SLEEP DISORDERED BREATHING; SOMATOFORM DISORDER; SUBSTANCE ABUSE; THYROID DISEASE; TREMOR;

EID: 84875283089     PISSN: 15734005     EISSN: 18756441     Source Type: Journal    
DOI: 10.2174/157340013805289699     Document Type: Article

References (60)

1. Hagerman PJ. The fragile X prevalence paradox. J Med Genet 2008; 45: 498-9.
2. Hagerman RJ, Leehey M, Heinrichs W, et al. Intention tremor, parkinsonism, and generalized brain atrophy in male carriers of fragile X. Neurology 2001; 57: 127-30.
3. Jacquemont S, Hagerman RJ, Leehey M, et al. Fragile X premutation tremor/ataxia syndrome: Molecular, clinical, and neuroimaging correlates. Am J Hum Genet 2003; 72: 869-78.
4. Tassone F, Hagerman RJ, Taylor AK, Gane LW, Godfrey TE, Hagerman PJ. Elevated levels of FMR1 mRNA in carrier males: a new mechanism of involvement in fragile X syndrome. Am J Hum Genet 2000; 66: 6-15.
5. Greco C, Berman RF, Martin RM, et al. Neuropathology of fragile X-associated tremor/ataxia syndrome (FXTAS). Brain 2006; 129: 243-55.
6. Hunsaker MR, Greco CM, Spath MA, et al. Widespread noncentral nervous system organ pathology in fragile X premutation carriers with fragile X-associated tremor/ataxia syndrome and CGG knock-in mice. Acta Neuropathol 2011; 122: 467-79.
7. Jacquemont S, Hagerman RJ, Leehey MA, et al. Penetrance of the fragile X-associated tremor/ataxia syndrome in a premutation carrier population. JAMA 2004; 291:460-9.
8. Coffey SM, Cook K, Tartaglia N, et al. Expanded clinical phenotype of women with the FMR1 premutation. Am J Med Genet 2008; 146A: 1009-16.
9. Rodriguez-Revenga L, Madrigal I, Pagonabarraga J, et al. Penetrance of FMR1 premutation associated pathologies in fragile X syndrome families. Eur J Hum Genet 2009; 17: 1359-62.
10. Leehey MA. Fragile X-associated tremor/ataxia syndrome: clinical phenotype, diagnosis, and treatment. J Investig Med 2009; 57: 830-6.
11. Hagerman PJ, Hagerman RJ. Fragile X-associated tremor/ataxia syndrome (FXTAS). Ment Retard Dev Disabil Res Rev 2004; 10: 25-30.
12. McConkie-Rosell A, Finucane B, Cronister A, Abrams L, Bennett RL, Pettersen BJ. Genetic counseling for fragile X syndrome: updated recommendations of the National Society of Genetic Counselors. J Genet Couns 2005; 14: 249-69.
13. Brunberg JA, Jacquemont S, Hagerman RJ, et al. Fragile X premutation carriers: Characteristic MR imaging findings in adult males with progressive cerebellar and cognitive dysfunction. Am J Neuroradiol 2002; 23: 1757-66.
14. Adams JS, Adams PF, Nguyen D, et al. Volumetric brain changes in females with fragile X-associated tremor/ataxia syndrome (FXTAS). Neurology 2007; 69: 851-9.
15. Farzin F, Perry H, Hessl D, et al. Autism spectrum disorders and attention-deficit/hyperactivity disorder in boys with the fragile X premutation. J Dev Behav Pediatr 2007; 27: S137-44.
16. Chonchaiya W, Au J, Schneider A, et al. Increased prevalence of seizures in boys who were probands with the FMR1 premutation and co-morbid autism spectrum disorder. Hum Genet 2012; 131: 581-9.
17. Chonchaiya W, Utari A, Pereira GM, Tassone F, Hessl D, Hagerman RJ. Broad clinical involvement in a family affected by the fragile X premutation. J Dev Behav Pediatr 2009; 30: 544-51.
18. Aziz M, Stathopulu E, Callias M, et al. Clinical features of boys with fragile X premutations and intermediate alleles. Am J Med Genet 2003; 121B: 119-27.
19. Goodlin-Jones BL, Tassone F, Gane LW, Hagerman RJ. Autism spectrum disorder and the fragile X premutation. J Dev Behav Pediatr 2004; 25: 392-8.
20. Basuta K, Narcisa V, Chavez A, et al. Clinical phenotypes of a juvenile sibling pair carrying the fragile X premutation. Am J Med Genet A 2011; 155A: 519-25.
21. Clifford S, Dissanayake C, Bui QM, et al. Autism spectrum phenotype in males and females with fragile X full mutation and premutation. J Autism Dev Disord 2007; 37: 738-47.
22. De Caro JJ, Dominguez C, Sherman SL. Reproductive health of adolescent girls who carry the FMR1 premutation. Ann NY Acad Sci 2008; 1135: 99-111.
23. McConkie-Rosell A, Devellis BM. Threat to parental role: a possible mechanism of altered self-concept related to carrier knowledge. J Genet Couns 2000; 92: 336-42.
24. Boughton M, Halliday L. A challenge to the menopause stereotype: young Australian women's reflections of 'being diagnosed' as menopausal. Health Soc Care Community 2008; 16: 565-72.
25. Hunter JE, Rohr JK, Sherman SL. Co-occurring diagnoses among FMR1 premutation allele carriers. Clin Genet 2010; 77: 374-81.
26. Roberts JE, Bailey D, Mankowski J, et al. Mood and anxiety disorders in females with the FMR1 premutation. Am J Med Genet Neuropsychiatr Genet 2009; 150B: 130-9.
27. Bourgeois JA, Seritan AL, Casillas M, et al. Lifetime prevalence of mood and anxiety disorders in fragile X premutation carriers. J Clin Psychiatry 2011; 72: 175-82.
28. Hessl D, Tassone F, Loesch DZ, et al. Abnormal elevation of FMR1 mRNA is associated with psychological symptoms in individuals with the fragile X premutation. Am J Med Genet Neuropsychiatr Genet 2005; 139B:115-21.
29. Kogan CS, Turk J, Hagerman RJ et al. Impact of the fragile X mental retardation 1 (FMR1) gene premutation on neuropsychiatric functioning in adult males without fragile X-associated tremor/ataxia syndrome: a controlled study. Am J Med Genet B Neuropsychiatr Genet 2008; 147B: 859-72.
30. Seritan AL, Schneider A, Olichney JM, Leehey MA, Akins RS, Hagerman RJ. Conversion disorder in women with the FMR1 premutation. Am J Med Genet 2009; 149: 2501-6.
31. Adams PE, Adams JS, Nguyen DV, et al. Psychological symptoms correlate with reduced hippocampal volume in fragile X premutation carriers. Am J Med Genet Neuropsychiatr Genet 2010; 153B: 775-85.
32. Hagerman RJ, Leavitt BR, Farzin F, et al. Fragile X-associated tremor/ataxia syndrome (FXTAS) in females with the FMR1 premutation. Am J Hum Genet 2004; 74: 1051-6.
33. Leehey MA, Legg W, Tassone F, Hagerman RJ. Fibromyalgia in fragile X mental retardation 1 gene premutation carriers. Rheumatology 2011; 50: 2233-6.
34. Chonchaiya W, Tassone F, Ashwood P, et al. Autoimmune disease in mothers with the FMR1 premutation is associated with seizures in their children with fragile X syndrome. Hum Genet 2010; 128: 539-48.
35. Hamlin A, Liu Y, Nguyen DV, Tassone F, Zhang L, Hagerman RJ. Sleep apnea in fragile X premutation carriers with and without FXTAS. Am J Med Genet B Neuropsychiatr Genet 2011; 156B: 923-8.
36. Hamlin A, Sukharev D, Campos L, et al. FMR1 premutation males with and without FXTAS and hypertension. Am J Med Genet 2012; 158A: 1304-9.
37. Chonchaiya W, Nguyen DV, Au J, et al. Clinical involvement in daughters of men with fragile X-associated tremor ataxia syndrome. Clin Genet 2010; 78: 38-46.
38. Hunter JE, Epstein MP, Tinker SW, Abramowitz A, Sherman SL. The FMR1 premutation and attention deficit hyperactivity disorder (ADHD): Evidence for a complex inheritance. Behav Genet 2012; 42: 415-22.
39. Rodriguez-Revenga L, Madrigal I, Alegret M, Santos M, Milà M. Evidence of depressive symptoms in fragile-X syndrome premutated females. Psyhiatr Genet 2008; 18: 153-155.
40. Hagerman RJ, Hagerman PJ, Seritan AL, Grigsby J. Fragile Xassociated tremor/ataxia syndrome (FXTAS): A novel dementia syndrome. Presented at the American Association of Geriatric Psychiatry Annual Meeting, Honolulu, HI, March 2009.
41. First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition (SCID-I/P). New York: Biometrics Research, New York State Psychiatric Institute, November 2002.
42. Wetzel HH, Gehl CR, Dellefave-Castillo L, et al. Suicidal ideation in Huntington disease: the role of comorbidity. Psychiatry Res 2011; 188: 372-6.
43. Seritan AL, McCloud MK, Hinton L. Geriatric depression - Review for primary care. Curr Psychiatry Rev 2009; 5: 137-42.
44. Ougrin D. Efficacy of exposure versus cognitive therapy in anxiety disorders: systematic review and meta-analysis. BMC Psychiatry 2011; 11: 200.
45. Kroenke K. Efficacy of treatment for somatoform disorders: A review of controlled trials. Psychosom Med 2007; 69: 881-8.
46. Arean P, Hegel M, Vannoy S, Fan M-Y, Unutzer J. Effectiveness of problem solving therapy for older, primary care patients with depression: Results from the IMPACT project. The Gerontologist 2008; 48: 311-23.
47. Brega AG, Goodrich G, Bennett RE, et al. The primary cognitive deficit among males with fragile X-associated tremor/ataxia syndrome (FXTAS) is a dysexecutive syndrome. J Clin Exp Neuropsychol 2008; 30: 853-69.
48. McConkie-Rosell A, Abrams L, Finucane B, et al. Recommendations from multi-disciplinary focus groups on cascade testing and genetic counseling for fragile X-associated disorders. J Genet Counsel 2007; 16: 593-606.
49. Hall DA, Berry-Kravis E, Hagerman RJ, Hagerman PJ, Rice CD, Leehey MA. Symptomatic treatment in the fragile X-associated tremor/ataxia syndrome. Mov Disord 2006; 21: 1741-3.
50. Hagerman RJ, Hall DA, Coffey S, et al. Treatment of fragile Xassociated tremor ataxia syndrome (FXTAS) and related neurological problems. Clin Interv Aging 2008; 3: 251-62.
51. Bourgeois JB, Farzin F, Brunberg JA, et al. Dementia with mood symptoms in a carrier of the fragile X-associated tremor/ataxia syndrome (FXTAS): clinical intervention with donepezil and venalafaxine. J Neuropsychiatry Clin Neurosci 2006; 18: 171-7.
52. Berry-Kravis E, Hall DA, Leehey MA, Hagerman RJ. Treatment and management of FXTAS. In: Tassone F, Berry-Kravis E, Eds. The Fragile X-Associated Tremor Ataxia Syndrome (FXTAS). New York: Springer. 2010, pp. 137-54.
53. Chow TW, Pollock BG, Milgram NW. Potential cognitive enhancing and disease modification effects of SSRIs for Alzheimer's disease. Neuropsychiatr Dis Treat 2007; 3: 627-36.
54. Martinowich K, Lu B. Interaction between BDNF and serotonin: role in mood disorders. Neuropsychopharmacology 2008; 33: 73-83.
55. Boldrini M, Underwood MD, Hen R, et al. Antidepressants increase neural progenitor cells in the human hippocampus. Neuropsychopharmacology 2009; 34: 2376-89.
56. Malik S, Arif H, Hirsch LJ. Lamotrigine and its applications in the treatment of epilepsy and other neurological and psychiatric disorders. Expert Rev Neurother 2006; 6: 1609-27.
57. Berger I, Segal I, Shmueli D, Saada A. The effect of antiepileptic drugs on mitochondrial activity: a pilot study. J Child Neurol 2010; 25: 541-5.
58. Napoli E, Ross-Inta C, Wong S, et al. Altered zinc transport disrupts mitochondrial protein processing/import in fragile Xassociated tremor/ataxia syndrome. Hum Mol Genet 2011; 20: 3079-92.
59. Ortigas MC, Bourgeois JA, Schneider A, et al. Improving fragile X-associated tremor/ataxia syndrome symptoms with memantine and venlafaxine. J Clin Psychopharmacol 2010; 30: 642-4.
60. Collins S, Sigtermans MJ, Dahan A, Zuurmond WA, Perez R. NMDA receptor antagonists for the treatment of neuropathic pain. Pain Medicine 2010; 11: 1726-42.